Kura Oncology, Inc. (KURA) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 5.61
30Y Low5.6·High5.6
P/B Ratio
↑
4.69
↑+74% vs avg
5yr avg: 2.70
30Y Low1.0·High5.2
ROE
↓
-94.8%
↑-108% vs avg
5yr avg: -45.5%
30Y Low-95%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KURA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kura Oncology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $819M | $911M | $750M | $1.1B | $831M | $929M | $1.7B | $577M | $494M | $356M | $110M |
| Enterprise Value | $680M | $773M | $543M | $1.0B | $794M | $845M | $1.4B | $558M | $485M | $351M | $108M |
| P/E Ratio → | -2.93 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 12.13 | 13.50 | 13.93 | — | — | — | — | — | — | — | — |
| P/B Ratio | 4.69 | 5.23 | 1.81 | 2.65 | 1.98 | 1.83 | 2.84 | 2.64 | 3.07 | 4.45 | 1.94 |
| P/FCF | — | — | 5.61 | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 5.59 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KURA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.45 | 10.07 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 4.05 | — | — | — | — | — | — | — | — |
KURA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Kura Oncology, Inc. earns an operating margin of -449.9%. Operating margins have compressed from -358.5% to -449.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -94.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.9% | 99.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating Margin | -449.9% | -449.9% | -358.5% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -412.9% | -412.9% | -322.9% | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -94.8% | -94.8% | -42.9% | -37.3% | -29.3% | -23.3% | -21.6% | -33.3% | -50.2% | -51.8% | -39.7% |
| ROA | -37.2% | -37.2% | -28.8% | -33.7% | -27.4% | -22.1% | -20.2% | -29.8% | -43.5% | -42.8% | -35.1% |
| ROIC | -188.5% | -188.5% | -49.7% | -32.7% | -26.1% | -27.2% | -27.5% | -28.7% | -41.4% | -41.6% | -35.1% |
| ROCE | -46.6% | -46.6% | -35.3% | -39.2% | -29.6% | -23.2% | -21.7% | -34.2% | -49.4% | -48.0% | -38.7% |
KURA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $149M exceeds total debt of $11M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.04 | 0.04 | 0.03 | 0.01 | 0.02 | 0.04 | 0.05 | 0.09 | 0.13 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.79 | -0.50 | -0.05 | -0.09 | -0.17 | -0.51 | -0.08 | -0.05 | -0.05 | -0.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -1.55 | — | — | — | — | — | — | — | — |
| Interest Coverage | -200.81 | -200.81 | -119.33 | -107.04 | -610.76 | -317.05 | -158.99 | -116.34 | -64.83 | -40.63 | -49.16 |
Net cash position: cash ($149M) exceeds total debt ($11M)
KURA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kura Oncology, Inc.'s current ratio of 6.06x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.26x to 6.06x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.06 | 6.06 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Quick Ratio | 6.05 | 6.05 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Cash Ratio | 5.70 | 5.70 | 9.24 | 12.02 | 18.21 | 23.07 | 24.34 | 15.22 | 13.15 | 9.29 | 12.44 |
| Asset Turnover | — | 0.09 | 0.07 | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.14 | 0.14 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 68.17 | — | — | — | — | — | — | — | — | — |
KURA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kura Oncology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 17.8% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $88M | $86M | $73M | $67M | $66M | $53M | $42M | $35M | $23M | $19M |
Peer Comparison
Compare KURA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KURAYou | $819M | -2.9 | — | — | 99.9% | -449.9% | -94.8% | -188.5% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 DAY | $11B | 635.1 | 37.7 | 65.2 | 46.1% | 5.9% | 0.7% | 2.5% | 3.9 |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 PRME | $562M | -2.3 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
See KURA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KURA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KURA vs MGNX
Side-by-side business, growth, and profitability comparison vs MacroGenics, Inc..
Start ComparisonKURA — Frequently Asked Questions
Quick answers to the most common questions about buying KURA stock.
What is Kura Oncology, Inc.'s P/E ratio?
Kura Oncology, Inc.'s current P/E ratio is -2.9x. This places it at the 50th percentile of its historical range.
What is Kura Oncology, Inc.'s ROE?
Kura Oncology, Inc.'s return on equity (ROE) is -94.8%. The historical average is -43.8%.
Is KURA stock overvalued?
Based on historical data, Kura Oncology, Inc. is trading at a P/E of -2.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Kura Oncology, Inc.'s profit margins?
Kura Oncology, Inc. has 99.9% gross margin and -449.9% operating margin.